Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20) (remove)
Language
- English (20)
Keywords
- multiple myeloma (14)
- CXCR4 (3)
- lenalidomide (3)
- medicine (3)
- molecular imaging (3)
- FDG (2)
- PET (2)
- amplicon sequencing (2)
- amyloidosis (2)
- bone disease (2)
- bortezomib (2)
- deformation (2)
- echocardiography (2)
- ejection fraction (2)
- pomalidomide (2)
- positron emission tomography (2)
- prognosis (2)
- stem-cell transplantation (2)
- theranostics (2)
- 18FDG-PET/CT (1)
- AKT-signaling (1)
- Antibodies (1)
- CXCR4/SDF-1 (1)
- FDG PET/CT (1)
- FDG-PET/CT (1)
- Hepatitis B virus reactivation (1)
- KRAS (1)
- MEK/ERK-signaling (1)
- Multiple myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- PET/CT (1)
- Positron emission tomography (1)
- SLAMF7 (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- abnormalities (1)
- adverse events (1)
- artificial intelligence (1)
- autologous transplantation (1)
- biosynthesis (1)
- bone marrow cells (1)
- bone remineralization (1)
- calcium imaging (1)
- cancer (1)
- cardiac transplantation (1)
- cell staining (1)
- cells (1)
- chemokine receptor (1)
- combination therapy (1)
- computed tomography (1)
- death rates (1)
- deletion 17P (1)
- depression (1)
- diagnostic medicine (1)
- elotuzumab (1)
- esophagogastric junction (1)
- experience (1)
- growth-factor receptor 3 (1)
- high-risk cytogenetics (1)
- imaging techniques (1)
- in vivo imaging (1)
- induction regimen (1)
- intergroupe francophone (1)
- involvement (1)
- kidney (1)
- lenalidomide-refractory patients (1)
- lesions (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- myeloma (1)
- natural language processing (1)
- newly diagnosed (1)
- observational (1)
- ontology (1)
- participation in clinical trials (1)
- plus dexamethasone (1)
- quality of life (1)
- radionuclide therapy (1)
- rare SNP (1)
- real world evidence (1)
- receptor tyrosine kinases (1)
- regression analysis (1)
- renal failure (1)
- safety (1)
- stem cell transplantation (1)
- survival (1)
- therapy (1)
- translocation (1)
- treatment response (1)
- whole-body imaging (1)
Institute
- Medizinische Klinik und Poliklinik II (18)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Pathologisches Institut (5)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Medizinische Klinik und Poliklinik I (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Humangenetik (1)
- Institut für Informatik (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
Sonstige beteiligte Institutionen
Background
The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (pom)/dex compared to pom/dex alone and resulted in licensing of this novel triplet combination, but clinical experience is still limited.
Purpose
To analyze the efficacy and safety of elo/pom/dex in a “real world” cohort of patients with advanced MM, we queried the databases of the university hospitals of Würzburg and Vienna.
Findings
We identified 22 patients with a median number of five prior lines of therapy who received elo/pom/dex prior to licensing within an early access program. Patients received a median number of 5 four-week treatment cycles. Median PFS was 6.4 months with 12-month and 18-month PFS rates of 35% and 28%, respectively. The overall response rate was 50% and 64% of responding patients who achieved a longer PFS with elo/pom/dex compared to their most recent line of therapy. Objective responses were also seen in five patients who had been pretreated with pomalidomide. Low tumor burden was associated with improved PFS (13.5 months for patients with ISS stage I/II at study entry v 6.4 months for ISS III), although this difference did not reach statistical significance. No infusion-related reactions were reported. The most frequent grade 3/4 adverse events were neutropenia and pneumonia.
Conclusion
Elo/pom/dex is an active and well-tolerated regimen in highly advanced MM even after pretreatment with pomalidomide.